A study was conducted to examine whether or not the histopathological therapeutic effects of preoperative chemotherapy could be useful for determining prognosis in women with locally advanced breast cancer. The patients were 37 women with locally advanced breast cancer who received preoperative chemotherapy between 1977 and 1987. The histological grade of malignancy (HGM) and histopathological therapeutic effects of chemotherapy (TEf) were examined in resected specimens. Patients with H G M 3 showed a poorer 10-year overall survival (38%) than those with H G M 1 or 2 (62%). Patients showing a better histopathological response (TEf 1b plus 2) had a poorer 10-year overall survival (20%) than those with a poorer response (TEf 0 plus / 1a) (60%). Therapeutic effects were significantly related to histological grade, nuclear atypia and mitotic index (P=0.03, 0.005 and 0.002, respectively). Histopathological therapeutic effects were not directly correlated with patient prognosis. Cox proportional hazard regression analysis revealed that mitotic index was the most significant prognostic factor related to 10-year overall survival.
Introduction
Some clinical trials on the efficacy of neoadjuvant chemotherapy for locally advanced breast cancer (LABC) have produced conflicting data. Although survival benefit has not yet been demonstrated, neoadjuvant chemotherapies have several advantages over post-surgical adjuvant chemotherapy for the treatment of LABC. These include; (a) early initiation of systemic therapy, (b) inhibition of postsurgical growth spurt, 6 ' (c) delivery of chemotherapy through the intact tumor vasculature, (d) in vivo assessment of response to chemotherapy, (e) down-staging of the primary tumor and lymph node metastases, 4 ' 7) (f) less radical localregional therapeutic methods. 8 ' In this study, to evaluate the survival benefit of neoadjuvant chemotherapy, particularly the relationship of histoReceived: January 19, 1996 Accepted: March 4, 1996 For reprints and all correspondence: Takashi Fukutomi, Department of Surgical Oncology, National Cancer Center Hospital, 1-1, Tsukiji 5-chome, Chuo-ku, Tokyo 104 pathological response to prognosis, we studied the correlation between the biological aggressiveness of LABC, its sensitivity to chemotherapy and patient survival.
Materials and Methods
Between 1977 and 1987, 37 patients with stage Illb breast cancer received neoadjuvant chemotherapy (either intra-arterial or oral) at the National Cancer Center Hospital, followed by radical mastectomy and postoperative chemotherapy. Intra-arterial chemotherapy was administered using a catheter via the internal thoracic artery and the subclavian artery. Dosages of drugs used for neoadjuvant chemotherapy are shown in Table I . Extended or standard radical mastectomies were performed about 4 weeks after the start of chemotherapy. For adjuvant therapy, CMF (CPA, MTX and ADM) or CAMF (CPA, MTX, 5FU and ADM) with/without Tamoxifen was used.
The resected specimens were evaluated histologically for the histological grade of malignancy (HGM) and the therapeutic effects of neoadjuvant chemotherapy (TEf). Histological grade was defined by modified criteria using a combination of architectural atypia, nuclear atypia and number of mitoses. 9 ' Mitotic index was defined as follows: score 1 indicates the presence of less than 5 mitoses in 10 high-power fields (HPF) (x400); score 2 indicates 5 to 10 mitoses in 10 HPF; score 3 indicates more than 10 mitoses in 10 HPF. TEf on cancer cells were evaluated histologically according to the General Rules for Gastric Cancer Study 10 ' as follows: TEf 0, no response; TEf la, less than one third of cancer cells showing degeneration or necrosis; TEf lb, between one third and two thirds of cancer cells showing degeneration or necrosis; TEf 2, viable cancer cells remaining in less than one third of the tissue; TEf 3, cancer lesions entirely eradicated or replaced by fibrosis. We used TEf in this study instead of Grade in order not to confuse histological grade of malignancy with the grade of therapeutic effects.
Estimated survival curves were drawn using the Kaplan-Meier method, and logrank test was used to evaluate differences in survival time. The frequencies of all categorical data were compared by trend test, and differences at P<0.05 were considered significant.
Results
The characteristics of the patients studied are shown in Table II . A high proportion of HGM 3 tumors was notable. The interval from the completion of chemotherapy until surgery, which is considered to be an important factor for evaluating the effect of chemotherapy, ranged from 3 to 30 days (median 8 days). Overall survival and disease-free survival of each subgroup according to the degree of therapeutic effects are illustrated in Figs, la and lb. The 10-year overall survivals of the TEf 0 plus la subgroup and the TEf lb plus 2 subgroup were 60% and 20%, respectively. Better responders showed poorer overall survival. As shown in Table III , tumors with a higher histological grade, a higher degree of nuclear atypia and a higher mitotic index tended to show a significantly better response to chemotherapy (P=0.031, P=0.005 and P=0.002, respectively).
Estimated overall survival curves and disease-free survival curves of the patient groups with HGM 1 or 2 tumors and HGM 3 tumors are illustrated in Figs. 2a and 2b. Patients with tumors showing a higher histological grade had lower overall survival and disease-free survival rates (P=0.15 and 0.12, respectively). The 10-year overall survival rates of patients with HGM 1, 2 and 3 were 100%, 60% and 34%, respectively. Figs. 3a and 3b show the estimated overall survival and disease-free survival curves for patient groups with tumors differing in Years after neoadjuvant chemotherapy Years after neoadjuvant chemotherapy Cox proportional hazard regression analysis was also used to investigate prognostic factors. Age, menopausal status, TEf, number of lymph node metastases, mitotic index, vascular invasion and lymphatic infiltration were included in the regresion Years after neoadjuvant chemotherapy Years after neoadjuvant chemotherapy A high mitotic index showed the highest conditional risk ratio and this was highly significant (Table IV) . In other models including histological grade, instead of mitotic index, all the conditional risk ratios for these factors decreased and became less statistically significant.
Discussion
The present study investigated associations among histological grade, mitotic index and TEf in patients with locally advanced breast cancer. It might be speculated that a high histological grade is the result of degenerative change induced by chemotherapy. However, we considered that histological grade after neoadjuvant chemotherapy still expressed its own biological characteristics for two reasons: there was a well-responding tumor that was evaluated as HGM 1, maintaining a low degree of nuclear atypia and a tubular growth pattern, and HGM 3 cancers showed a poor prognosis despite a good response to chemotherapy. Our previous study had demonstrated that radiotherapy did not change biological aggressiveness as reflected by p53 and c-erbB-2 expression in breast cancer cells. ' Considering these facts, the correlation between them suggested that a higher histological grade and mitotic index indicated a higher sensitivity to chemotherapy.
Some previous reports have mentioned that a better histological response to neoadjuvant chemotherapy is correlated with better survival. 1 -13) On the other hand, our univariate analysis revealed a contrary trend, as shown in Fig. 3 . This difference might have been due to the absence of complete responders in our patient cohort. HGM 3 cancers responded well, but viable cancer cells did not disappear completely, and the remaining viable cells would have grown quickly, resulting in a bad outcome. This was partly because the drug dosages in our series were relatively low. One report has suggested that non-curative reduction of the tumor cell burden might result in increased proliferation of the residual tumor cells, due possibly to release of serum growth factors. 6 ' Thus, for neoadjuvant chemotherapy, a dose of anticancer drugs sufficient to kill the tumor cells completely is needed.
Predictability of the response to adjuvant chemotherapy has been reported in patients with node-positive breast cancer. 14 ' Patients randomly received one of three regimens (a low-, moderate-, or high-dose regimen of CMF), and some molecular markers including c-erbB-2 were evaluated in the resected specimens. Patients with the high-dose regimen achieved significantly longer survival if their tumors had c-erbB-2 overexpression, whereas patients without c-erbB-2 expression did not. It was concluded that overexpression of c-erbB-2 may be a useful marker for identifying patients who are most likely to benefit from high-dose adjuvant chemotherapy. In another study, c-erbB-2 amplification was found to be correlated with HGM 3 cases in invasive breast cancer. 15 ' These data suggested that patients with cancers showing high proliferation, as expressed by HGM 3 and c-erbB-2 amplification, were most likely to benefit from intensive treatment. Thus, it may be possible to assess treatment on the basis of these features for each tumor preoperatively using needle biopsy.
Cox proportional hazard regression analysis showed that lymphatic infiltration was an adverse prognostic factor. Clinically, lymphatic infiltration should be classified as present or absent, but statistically in this model a classification was made between 0 plus 1 and 2 plus 3 because of the large bias in the number of patients. When the analysis excluded lymphatic infiltration, the risk ratio for the other factors decreased and became nonsignificant. The reason for this is unknown, and for further clarification, analysis of a larger number of cases is necessary.
In conclusion, mitotic index was found to be the most significant prognostic factor for 10-year overall survival, and histologically evident therapeutic effects were not directly correlated with patient prognosis.
